Genetic and chemical knockdown: A complementary strategy for evaluating an anti-infective target

Advances and Applications in Bioinformatics and Chemistry

Volumn 6, Issue 1, 2013, Pages 1-13

  Ramachandran, Vasanthi ^a   Singh, Ragini ^b   Yang, Xiaoyu ^a   Tunduguru, Ragadeepthi ^a   Mohapatra, Subrat ^b   Khandelwal, Swati ^b   Patel, Sanjana ^b   Datta, Santanu ^b  

^a ASTRAZENECA   (United Kingdom)

^b Cellworks Research India   (India)

Author keywords

In silico; Inhibition; Knockdown; Vulnerability

Indexed keywords

EID: 84875272384     PISSN: None     EISSN: 11786949     Source Type: Journal    
DOI: 10.2147/AABC.S39198     Document Type: Article

References (30)

1. Chan PF, Holmes DJ, Payne DJ. Finding the gems using genomic discovery: antibacterial drug discovery strategies - the successes and the challenges. Drug Discov Today Ther Strateg. 2004;1:519-527.
2. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6:29-40.
3. Black MT, Bruton G. Inhibitors of bacterial signal peptidases. Curr Pharm Des. 1998;4:133-154.
4. Eisenthal R, Cornish-Bowden A. Prospects for antiparasitic drugs. The case of Trypanosoma brucei, the causative agent of sleeping sickness. J Biol Chem. 1998;273:5500-5505.
5. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007;130:797-810.
6. Barve A, Gupta A, Solapure SM, et al. A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli. Adv Appl Bioinform Chem. 2010;3:97-110.
7. Datta S. Understanding the characteristics of a good anti-infective drug target. J Parasitic Dis. 1999;23:139-140.
8. Kaur P, Agarwal S, Datta S. IPTG inducible promoter system for delineating bacteristatic and bactericidal targets in mycobacteria. PloS One. 2009;4:e5923.
9. Pollegioni L, Schonbrunn E, Siehl D. Molecular basis of glyphosate resistance-different approaches through protein engineering. FEBS J. 2011;278:2753-2766.
10. Bentley R. The shikimate pathway - a metabolic tree with many branches. Crit Rev Biochem Mol Biol. 1990;25:307-384.
11. de María N, Becerril JM, García-Plazaola JI, Hernandez A, De Felipe MR, Fernandez-Pascual M. New insights on glyphosate mode of action in nodular metabolism: role of shikimate accumulation. J Agric Food Chem. 2006;54:2621-2628.
12. Oliveira JS, Pinto CA, Basso LA, Santos DS. Cloning and overexpression in soluble form of fuctional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis. Protein Expr Purif. 2001;22:430-435.
13. Oliveira JS, Mendes MA, Palma MS, Basso LA, Santos DS. One step purification of 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis. Protein Expr Purif. 2003;28: 287-292.
14. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
15. Webb MR. A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci U S A. 1992;89:4884-4887.
16. Molecular Probes. EnzChek Phosphate Assay Kit (E-6646) product information. 2002. Available from: http://probes.invitrogen.com/media/pis/mp06646.pdf. Accessed December 2, 2012.
17. Bowden SD, Ramachandran VK, Knudsen GM, Hinton JC, Thompson A. An incomplete TCA cycle increases survival of Salmonella typhimurium during infection of resting and activated murine macrophages. PLoS One. 2010;5:e13871.
18. Singh A, Karimpour-Fard A, Gill RT. Increased mutation frequency in redox-impaired Escherichia coli due to RelA- and RpoS-mediated repression of DNA repair. Appl Environ Microbiol. 2010;76:5463-5470.
19. Alibhai MF, Stallings WC. Closing down on glyphosate inhibition - with a new structure for drug discovery. Proc Natl Acad Sci U S A. 2001;98:2944-2946.
20. Huynh QK, Kishore GM, Bild GS. 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Escherichia coli, identification of Lys-22 as a potential active site residue. J Biol Chem. 1988;263:735-739.
21. Shuttleworth WA, Evans JNS. Site-directed mutagenesis and NMR studies of histidine-385 mutants of 5-enolpyruvylshikimate 3-phosphate synthase enzymes. Biochemistry. 1994;33:7062-7068.
22. Shuttleworth WA, Pohl ME, Helms GL, Jakeman DL, Evans JN. Site-directed mutagenesis of putative active site residues of 5-enolpyruvylshikimate 3-phosphate synthase enzymes. Biochemistry. 1999;38:296-302.
23. Eschenburg S, Healy ML, Priestman MA, Lushington GH, Schönbrunn E. How the mutation glycine96 to alanine confers glyphosate insensitivity to 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Escherichia coli. Planta. 2002;216:129-135.
24. Sharma U. Current possibilities and unresolved issues of drug target validation in Mycobacterium tuberculosis. Expert Opin Drug Discov. 2011;6:1171-1186.
25. Sauro HM. Enzyme Kinetics for Systems Biology. Lexington (KY): Ambrosius; 2011.
26. Larsson E, Sander C, Marks D. mRNA turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol. 2010;6:433.
27. Li L, Lu W, Han Y, et al. A novel RPMXR motif among class II 5-enolpyruvylshikimate-3-phosphate synthases is required for enzymatic activity and glyphosate resistance. J Biotechnol. 2009;144: 330-336.
28. Peng L, Arauzo-Bravo MJ, Shimizu K. Metabolic flux analysis for a ppc mutant Escherichia coli based on 13C-labelling experiments together with enzyme activity assays and intracellular metabolite measurements. FEMS Microbiol Lett. 2004;235:17-23.
29. Fong SS, Nanchen A, Palsson BO, Sauer U. Latent pathway activation and increased pathway capacity enable Escherichia coli adaptation to loss of key metabolic enzymes. J Biol Chem. 2006;281:8024-8033.
30. Sauer U, Canonaco F, Heri S, Perrenoud A, Fischer E. The soluble and membrane-bound transhydrogenases UdhA and PntAB have divergent functions in NADPH metabolism of Escherichia coli. J Biol Chem. 2004;279(8):6613-6619.